NCT01480271 - An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Rhinitis, Allergic, Seasonal

Interventions

DRUG

2 ng GSK2445053

2ng GSK2445053 administered intranasally

DRUG

20ng GSK2445053

20ng GSK2445053 administered intranasally

DRUG

100ng GSK2445053

100ng GSK2445053 administered intranasally

DRUG

200ng GSK2445053

200ng GSK2445053 administered intranasally

DRUG

400ng GSK2445053

400ng GSK2445053 administered intranasally

DRUG

1000ng GSK2445053

1000ng GSK2445053 administered intranasally

DRUG

2000ng GSK2445053

2000ng GSK2445053 administered intranasally

DRUG

4000ng GSK2445053

4000ng GSK2445053 administered intranasally

DRUG

Placebo

Placebo administered intranasally

Trial Locations (1)

GSK Investigational Site, Zuidlaren